2011~2012 annual report

neurosciencesvictoria

CONTENTS

CHAIRMAN AND CEO REPORT

Neurosciences Victoria has completed its twelfth year of operations and on behalf of the Board of the Company, we are pleased to report on another year of solid achievement.

Bill Burdett
Chairman

Andrew Milner PhD
Chief Executive Officer and Managing Director

Our operational activities in 2011/12 generated a loss of $184,000, in part reflecting a difficult year for program funding from both government and industry. In addition, a number of Company initiatives are strategically important but have timelines of 2 - 3 years to fruition. Whilst any loss is a concern, the impact should be seen in the context of our total equity at 30 June 2012 of $2,572,000.

The Company will increase its marketing activities with industry in Asia and Europe over the coming year, highlighting the world class neuroscience cluster in Melbourne and positioning NSV as a highly effective channel to facilitate commercial interactions with our Member organisations. This will build on our recent successes in working with Members to license innovative software used for Magnetic Resonance Imaging to a major European manufacturer and developing a supply contract with a major US pharmaceutical company for accessing a large patient cohort.

We are very pleased to be working with the Victorian Government to assist the Department of Health in administering the Mental Illness Research Fund. This is a $10m initiative over 4 years aimed at supporting collaborative research targeting better outcomes for Victorians with mental illness and their families/carers. Such initiatives are critical for the development of new knowledge across Victoria's research, treatment and support sectors which can be applied to improve treatment and recovery outcomes for people with mental illness.

Additionally, we have partnered with Austin Health to obtain funding from the Transport Accident Commission to establish the Spinal Research Institute. The Institute is based at Austin Health, with Associate Professor Doug Brown as Director. The Spinal Research Institute aims to develop infrastructure and build capacity for research into spinal injury to improve the welfare of spinal cord injury patients, their families and carers, for the long term benefit of the Victorian community. The Spinal Research Institute will ensure the viability of spinal cord injury (SCI) research and provide infrastructure for research involving patients with spinal injuries. This will maximise translation of research output and bring the latest advances to clinical practice and patient care.

Our inaugural NSV Brain and Mind Scholarships were awarded in 2012 to two high performing applicants undertaking research degrees at Royal Melbourne Hospital and the Murdoch Children's Research Institute. The Company believes research-trained clinical neuroscience practitioners are a major asset for neuroscience in Victoria and the Scholarships are intended to encourage graduate research as a viable option for clinicians. We will offer two more scholarships for 2013.

In other operational activities, NSV continues to be successful in generating partnerships and licensing activities for our Members with both the private and public sectors. NSV is particularly well placed to facilitate major cross-institute, multi-disciplinary programs. Major initiatives in sports injury, computational neuroscience, imaging and psychiatric illness are underway. It is clear from these initiatives that Melbourne has the critical mass and scientific leadership to justify its position at the forefront of neuroscience.

We expect 2012/13 will be a strong year for NSV and Victorian neuroscience as we continue to expand our activities and develop new opportunities in areas of major unmet medical need.

We would like to thank all of our Members, fellow Directors, NSV's staff and our valued colleagues in the Melbourne neuroscience community for their continued support and involvement.

NEUROSCIENCES VICTORIA OVERVIEW

Neurosciences Victoria is the marketing organisation for an Australian world-class neuroscience cluster. We offer a single access point to a series of neuroscience technology-based platforms and disease specialisations, backed by leading neurology and psychiatry resources and clinical expertise.

One of our main aims is to facilitate seamless contractual relationships between industry, government and the neuroscience cluster of universities, medical research institutes and major hospitals. To date, NSV has generated in excess of $70m in revenues for the neuroscience cluster.

The principal products and services of NSV relate to the pre-clinical and clinical neuroscience expertise in pharmaceuticals, diagnostics and medical devices relevant to the global marketplace which reside within our Member organisations. The major product opportunities relate to contract services in which revenue is generated from external customers who access the skills and infrastructure within the Member organisations.

NSV typically acts as a conduit for external customers for large scale, multi-institute programs. This ability to act as a 'one-stop shop' is one of the key competitive advantages of NSV, both within Australia and internationally.

NSV also provides advice and leadership to other business activities within its membership such as the provision of high-level management and assistance in financing activities to spin-out companies.

NSV operates as a self-sustaining business, growing revenues and controlling costs to ensure its viability for the foreseeable future.

Capabilities and Disease Specialisations

NSV markets the following Technology Platforms.

- **Neuroscience Trials Australia**
  Facilities include Clinical Trial Design (assessment of feasibility, assistance with human ethics approvals, matching study sponsors with suitable investigators) and Databases (design and management, access to existing databases and data collection).
- **Neuro Research Services**
  Facilities include Rodent Surgical Techniques, Advance Morphology and Microscopy, In Vivo Pre-clinical Testing and Behavioural Phenotyping.
- **Cellular Physiology, Histology and Imaging**
  Facilities include the Confocal Microscope, Electrophysiological Testing, Evaluation of Channels as Targets, Immunohistochemistry and Histology.
- **Clinical Neurobiology of Psychiatry**
  Facilities include EEG/ERP Systems, a GAITrite Gait Analysis System, an Eyelink Video Eye Tracking System and a Transcranial Direct Current Stimulator.
- **Neuroimaging**
  Facilities include PET, Large Bore MRI, Small Animal MRI and Informatics.
- **Neuroproteomics and Neurogenomics**
  Facilities include Genomics Sequencing and Genotyping, Real Time PCR, Protein Arrays and Expression, SELDI, HPLC and Bioinformatics.
- **Australian Brain Bank Network**
  Facilities include Application Specific Brain Banks, Research Material, Neuropathologic Diagnostic Service and a Brain Donor program.

NSV works with the following Disease Specialisations.

- Multiple Sclerosis
- Schizophrenia
- Alzheimer's Disease
- Epilepsy
- Neurodevelopmental Disease
- Depression and Bipolar Disorder
- Huntington's Disease
- Motor Neurone Disease/ALS
- Neurotrauma
- Parkinson's Disease
- Stroke

BOARD OF DIRECTORS

The Board of Directors of Neurosciences Victoria, chaired by Mr Bill Burdett, brings together a balance of scientific, clinical, public policy and commercial expertise.

Mr Bill Burdett

BSc (Hons), ASIA

CHAIRMAN

Mr Burdett graduated in geology at the University of Western Australia and worked in oil exploration for nine years before moving to Melbourne to start a mining research department for the stockbroking firm of A.C. Goode & Co. He became a partner of the firm and in 1984 was appointed Executive Director in charge of Institutional Sales, Research and Corporate Finance.

Following the sale of A.C. Goode & Co. to National Australia Bank in 1987, Bill was Founding Chairman and Chief Executive of Burdett, Buckeridge & Young, an institutional stockbroker.

He is currently a Director of Investment Technology Group, Inc. (ITG), listed on the New York Stock Exchange.

Mrs Jan West AM

B.Comm, FCA GAICD

DEPUTY CHAIR

Ms West is a non-Executive Director with experience in public sector, community and private organisations. A Chartered Accountant with 23 years' experience as a Partner at Deloitte, Jan is a member of the Financial Reporting Council and a past President of The Institute of Chartered Accountants in Australia. She is a Director of Places Victoria, Australian Red Cross and Retail Responsible Entity Ltd. Jan's experience offers the Board a depth of knowledge and skills in audit, corporate governance, risk and general business acumen.

She was awarded membership of the Order of Australia in 2007 and the Governor General's Centenary Medal in 2003. Jan is a Fellow of the ICAA and of CPA Australia and a Member of the Australian Institute of Company Directors.

Dr Andrew Milner

BSc (Hons), MSc, PhD, FASM

CHIEF EXECUTIVE OFFICER AND MANAGING DIRECTOR

Dr Milner has been the CEO and Managing Director of Neurosciences Victoria since 2006.

Andrew obtained a BSc (Hons) at the University of Melbourne in 1976, a MSc degree at the University of Melbourne in 1980 and a PhD at the John Curtin School of Medical Research at the Australian National University in 1983.

Andrew is a Member of the Spinal Research Institute, a Member of the Advisory Board of the Melbourne Neuroscience Institute at the University of Melbourne and was appointed CEO of Neurosciences Australia in 2006.

Andrew is a Fellow of the Australian Society for Microbiology and has worked in animal health and agriculture as Head of Molecular Biology at the Victorian Institute of Animal Science and subsequently as Operations Manager at Daratech Pty Ltd. In the medical arena, he has worked as Pricing Manager for Zeneca and AstraZeneca in Australia, as Director of Development and Commercialisation for Kendle (Australia) and as Managing Director of Mimotopes Pty Ltd.

Professor Stephen Davis

MD, FRCP, Edin FRACP

Professor Davis is the inaugural Professor of Translational Neuroscience at the University of Melbourne. He is based at the Royal Melbourne Hospital (RMH) where he is the Director of Neurosciences and Continuing Care, Director of Neurology and Director of the Melbourne Brain Centre at the RMH.

He is the immediate past-President of the Australian and New Zealand Association of Neurologists (ANZAN) and a past-President of the Stroke Society of Australasia. He was the first Co-Chair of the Australasian Stroke Trials network and has extensive experience in stroke trials. He is a Board Member of the World Stroke Organisation and Co-Chair of the World Stroke Academy. He is the Co-Chair, with Professor Geoffrey Donnan, of Neuroscience Trials Australia. He is a Consulting Editor for *Stroke* and Associate Editor for *Cerebrovascular Diseases*. He has been a Trustee of the RMH Neuroscience Foundation since its formation in 1992.

He was given the M.J. Eadie Award in 2004 by the Australian and New Zealand Association of Neurologists for career achievements in neuroscience research, and the Victorian Health Minister's Award for outstanding individual achievement in the 2008 Victorian Public Healthcare awards. He is the 2011 recipient of the William Feinberg Award from the American Stroke Association and the 2011 recipient of the Bethlehem Griffiths Research Foundation Medal.

He is the joint recipient of a National Health and Medical Research Council program grant in stroke. He has co-authored 3 books, numerous book chapters, and over 300 peer-reviewed papers.

His major research interests involve clinical trials in stroke and the use of neuroimaging, particularly multimodal MRI, in the selection of acute stroke treatments. He is the Co-PI with Professor Donnan of the EXTEND trial, a stroke trial aimed at extending the time window for thrombolysis using MRI in treatment selection.

Professor Geoffrey Donnan AO

MD, FRACP, FRCP

Professor Donnan is the Director of the Florey Neuroscience Institutes. He is Professor of Neurology, University of Melbourne and is the past Director of the National Stroke Research Institute.

Geoff's research interest is clinical stroke management and he was co-founder of the Australian Stroke Trials Network and Neuroscience Trials Australia. He is past President of the World Stroke Organisation and received the American Stroke Association William Feinberg Award for excellence in clinical stroke research in 2007. In 2012 he was appointed an Officer of the Order of Australia for his distinguished service to neurology and research contributions.

Professor Paul Fitzgerald

MBBS, MPM, PhD, FRANZCP

Professor Fitzgerald is Professor of Psychiatry, Deputy Director and Consultant Psychiatrist at the Monash Alfred Psychiatry Research Centre, a joint research centre of Monash University and the Alfred Hospital in Melbourne. He is also the Director of the TMS program and research unit at The Victoria Clinic, Prahran.

He is a qualified psychiatrist, has a Masters of Psychological Medicine and research PhD. He runs a substantive research program utilising brain stimulation and neuroimaging techniques including transcranial magnetic stimulation, functional and structural MRI, EEG and near infrared spectroscopy. The program has focused on the conduct of investigative studies of brain function / dysfunction as well as the conduct of a variety of novel clinical trials in mood, psychotic and developmental disorders.

Professor John Furness

MSc, PhD, FAA

Professor Furness is the Head of the Autonomic Neuroscience, Pain and Sensory Mechanisms Laboratories, Department of Anatomy and Neuroscience at the University of Melbourne. He is the Deputy Director of the Spinal Research Institute, Platform Leader of the Cell Physiology, Histology and Imaging Platform, and Leader of the Australian Phenomics Network (Melbourne).

He is best known for the chemical coding hypothesis that has strongly influenced studies of the organisation of nerve circuits, for his work in unravelling the intrinsic circuits in the digestive tract and for the discovery and characterisation of sensory neurons intrinsic to the digestive tract.

The major focuses of John's current work are on autonomic consequences of spinal cord injury, autonomic neuropathies, visceral sensory neurons, the investigation of drugs that reduce visceral pain and on the control of ion channels that determine the excitabilities of neurons.

He was elected a Fellow of the Australian Academy of Science in 1989. He received the Janssen International Research Award in 1993, the Davenport Medal of the American Physiological Society in 1997, the Distinguished Achievement Award of the Australian Neuroscience Society in 2003 and a Centenary Medal in 2003. He was elected Fellow of the Academy of Science of Bologna (L'accademia delle scienze dell'istituto di Bologna), the world's second oldest scientific academy, in 2005. John is also a Board Member of The Garnett Passe and Rodney Williams Memorial Foundation.

Professor Graeme Jackson

BSc (Hons), MD, FRACP

Professor Jackson is Deputy Director of the Florey Neuroscience Institutes, Director of the Brain Research Institute and a Professorial Fellow of the Department of Medicine, Austin Health.

His primary research interest is the application of Magnetic Resonance Imaging (MRI) techniques to the understanding of epilepsy and brain function. Graeme is a neurologist at the Austin Hospital. He was awarded the National Health and Medical Research Council Excellence Award (2008).

Graeme's major research achievement is his impact on the understanding of epilepsy. He is a world leader on the use of imaging technologies in neurological disease and has combined these interests to advance the understanding of epilepsy and to identify lesions that allow surgical cure of epilepsy.

DIRECTORS
(CONTINUED)

Mr Bruce Kean AM

Dip ChemE, FIEAus, FTS, FAICD, FRSA

Mr Kean was educated in Melbourne, studying chemical engineering and economics. He has served on the boards of many public companies, including as Managing Director of Boral Ltd (1987-1994) and a Director of AMP (1989-2000).

In community affairs, Bruce is Chair of the ATSE Clunies Ross Foundation. He is a Director of the APEC Study Centre Advisory Board of the Royal Melbourne Institute of Technology and is a Governor of the Florey Neuroscience Institutes.

He was Chair of the Committee for Economic Development of Australia (1994-2002), Chair of The Sir David Martin Foundation (1994-1998) and Chair of The Mental Health Research Institute of Victoria (2001-2008). He was a Member of the Prime Minister's Economic and Planning Advisory Committee (1992-1994) and Chair of the Commonwealth Government's Committee of Inquiry into the Standards and Conformance Infrastructure of Australia (1994-1995). In 1994 he was awarded the Order of Australia and later the Governor General's Centenary Medal.

Professor Trevor Kilpatrick

MBBS, PhD, FRACP

Professor Kilpatrick is a clinician scientist whose basic research focuses on the neurobiology of multiple sclerosis, in particular oligodendrocytic biology and regenerative medicine.

Trevor has initiated a number of productive clinical research projects and established multicentre collaborations to study the genetics and epidemiology of MS and is developing translational platforms for therapeutics that target neurodegenerative diseases.

He is Director of the Centre for Neuroscience Research and the Melbourne Neuroscience Institute at The University of Melbourne. He also heads the Multiple Sclerosis Division at the Florey Neuroscience Institutes and is a neurologist and Head of the MS Unit at the Royal Melbourne Hospital.

Company Secretary

Ms Marion Thompson

Ms Thompson has an extensive background in providing executive support at the senior level. Prior to joining NSV in 2002 she spent some 20 years in the Victorian public sector in positions at Museum Victoria and the former Land Conservation Council.

Professor Colin Masters

B Med Sci (Hons), MBBS, MD, Hon. DLitt W.Aust., FRCPath, FRCPA, FAA, FTSE

Professor Masters is a leader in research into Alzheimer's disease and other neurodegenerative diseases, including Creutzfeldt-Jakob and other prion diseases. His work over the last 36 years is widely acknowledged as having had a major influence on Alzheimer's disease research world-wide. This work has led to the continued development of novel drugs and therapeutic strategies to treat these diseases.

Colin is the Director of the Mental Health Research Institute and Laureate Professor at the University of Melbourne. He is the Chair of the National Health and Medical Research Council's Transmissible Spongiform Encephalopathies Advisory Committee and a consultant in neuropathology at the Royal Melbourne Hospital.

His achievements have been recognised by the receipt of many international awards - including the King Faisal International Prize in Medicine (1996), the Grand Hamdan International Award for Medical Sciences (2006), the Victoria Prize from the Minister for Innovation (2007) and the CSIRO Medal for Research Achievement (2011).

Professor Christopher Rowe

FRACP, MD

Professor Rowe is the Director of the Department of Nuclear Medicine and Centre for PET and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Melbourne.

He has published extensively on SPECT in epilepsy and beta-amyloid imaging in Alzheimer's disease. Chris applies state-of-the-art neuroimaging technology to develop and confirm new diagnostic tests and biomarkers.

Chris is a Professorial Fellow, University of Melbourne and Mental Health Research Institute, the Neuroimaging Stream Leader of AIBL Study of Ageing and the CRC for Mental Health and Chair, Neuroimaging Professional Interest Area, US Alzheimer's Association.

In 2011 he received the Kuhl-Lassen Award, US Society of Nuclear Medicine, for his work in developing a test for the treatment of epilepsy and the diagnosis of Alzheimer's disease. He is the first Australian researcher to receive a major international award from this Society.

Retired

Professor Bruce Tonge retired as a Director of Neurosciences Victoria on 14 November 2011.

BOARD ADVISORY COMMITTEES

Risk and Audit Committee

The Risk and Audit Committee is a Committee of the NSV Board and oversees the audit and risk functions of the Company. The Committee is comprised of the Chair of the Board and non-executive Independent Directors.

The primary objective of the Committee is to assist the Board in fulfilling its responsibilities by:

- Overseeing the internal control functions of the Company and its corporate entities
- Reviewing the relationship of those functions to external audit
- Reviewing the financial statements and reports
- Identifying the areas of risk affecting the Company and its corporate entities
- Monitoring the Company's development, implementation and audit of policies and practices in relation to risk
- Monitoring compliance with law
- Assisting the Company to identify and manage risks and opportunities in the commercialisation of intellectual property
- Reviewing proposals for resource allocation and making recommendations to the Board

The Committee also oversees the activities of its subcommittee, the Remuneration Committee, which has carriage of the remuneration framework and level for the CEO as well as the CEO's performance plan.

MEMBERSHIP

- Ms Jan West AM (Chair)
- Mr Bill Burdett
- Mr Bruce Kean AM

Scientific Advisory Council

The Scientific Advisory Council is a Committee of the NSV Board, established to generate initiatives and facilitate collaboration and the sharing of knowledge, skills and resources across a widely representative neuroscience community. The Council plays a role in policy development, advises the Board on scientific strategy and particular projects with the potential for commercialisation as well as options for infrastructure enhancements to further neuroscience research.

The Council has been a highly effective body since NSV's inception. Its structure is being reviewed at present to ensure its activities are optimised for the benefit of the neuroscience community.

MEMBERS

NSV represents these Melbourne-based leading neuroscience research organisations.

- Austin Health
- Bionics Institute
- Centre for Eye Research Australia
- Florey Neuroscience Institutes
  - *Brain Research Institute*
  - *Howard Florey Institute*
  - *National Stroke Research Institute*
- Melbourne Health
- Mental Health Research Institute
- Monash University
- Swinburne University of Technology
- University of Melbourne

The Neurosciences Victoria Annual Report reflects the period 1 July 2011 to 30 June 2012. The *Florey Neuroscience Institutes* and the *Mental Health Research Institute* will amalgamate on 1 August 2012 to form the *Florey Institute of Neuroscience and Mental Health.*

AUSTIN HEALTH

Austin Health is the major provider of tertiary health services, health professional education and research in the north-east of Melbourne and is world renowned for its research and specialist work in neurology, cancer, liver transplantation, spinal cord injuries, endocrinology, mental health and rehabilitation.

Eight independent research institutions are based at Austin Health, where leading research on cancer, diabetes, respiratory disease, liver disease, heart disease, stroke, epilepsy and psychiatry is conducted. In 2011, the Melbourne Brain Centre opened at the Austin Hospital at Heidelberg, housing some of Australia's top researchers in neurosciences and mental health.

In the area of neuroscience, Austin Health is a leader in the diagnosis and management of epilepsy, stroke and dementia and has sub-specialist clinics for these and other neurological disorders including Parkinson's disease and Multiple Sclerosis.

The Austin Health Centre for PET is a world leader in the development of scans for earlier and more accurate detection of Alzheimer's disease, Parkinson's disease and other neurodegenerative conditions. It is the Australian imaging lead site for national and international multi-centre studies such as the Australian Imaging, Biomarkers and Lifestyle study of Ageing (AIBL), the Dominantly Inherited Alzheimer's Network (DIAN) and the CRC for Mental Health. The neuroscience research group within the Centre for PET has extensive collaborations with both academic sites and major pharma companies worldwide.

Professor Christopher Rowe, the leader of the neuroscience PET research team and the Director of Nuclear Medicine and the Centre for PET was awarded the Kuhl Lassen Award for outstanding contribution to brain imaging by the US Society of Nuclear Medicine in 2011. His group publishes 25 papers per year and receives over $1.5 million annually in research funds. The Centre for PET provides direction, expertise and radiopharmaceuticals for the new PET research facility at the Melbourne Brain Centre in Parkville.

Vision

Austin Health will be renowned for excellence and outstanding leadership in healthcare, research and education.

Mission

Austin Health is the major provider of tertiary health services, and health professional education and research in the north-east of Melbourne.

Values

Our values guide our behaviour.

- **Integrity** - we exercise honesty, candour and sincerity
- **Accountability** - we are transparent, responsible and answerable
- **Respect** - we treat others with dignity, consideration, equality and value
- **Excellence** - we continually strive for excellence

www.austin.org.au

BIONICS INSTITUTE

The Bionics Institute (formerly the Bionic Ear Institute) is an independent, non-profit, research organisation working in the field of medical bionics. Medical bionics aims to replace and/or monitor impaired sensory or other functions using electronic devices that interface with the human body. The experience and discoveries gained from over 25 years of research on the cochlear implant led to developments in other areas of medical bionics. The Institute changed its name in June 2011 to reflect the breadth of its research activities.

Using a multidisciplinary approach, along with proven experience of working from conception to commercialisation, the Bionics Institute's research aims to deliver technologies to secure better health outcomes for people, reducing the burden of disease and disabilities. The Institute's researchers come from a diverse range of disciplines including neurology, biology, audiology, physiology, engineering, clinical research, speech science, mathematics and materials science.

The Institute has three key research areas.

Bionic Hearing

Research at the Bionics Institute is aimed at improving the performance of the cochlear implant and enabling its application to many more adults and children with hearing impairments. Specific projects include sound processing research to enhance the perception of music and speech, the development of techniques to improve the function of the hearing nerve and investigation of how the brain responds to long-term artificial stimulation.

Bionic Vision

As part of the Bionic Vision Australia consortium, the Bionics Institute is developing a bionic implant capable of restoring limited vision to people suffering from eye diseases such as retinitis pigmentosa. The Institute is using its engineering expertise and its experience in safety and biocompatibilty studies to establish safe surgical procedures and effective electrical stimulation strategies.

Neurobionics

In the Bionics Institute's Neurobionics research program, implantable devices are being developed to detect, predict and suppress abnormal neural activity in the brain or elsewhere in the body. The focus of this work is to develop a platform technology that can be used to treat a wide range of neurological disorders that have not responded to conventional treatments, including: drug-resistant epilepsy; certain severe psychiatric conditions (e.g. obsessive compulsive disorder); movement disorders (e.g. essential tremor); and chronic pain.

The Bionics Institute collaborates extensively with scientists, engineers, clinicians and surgeons to develop a multidisciplinary approach to research outcomes.

www.bionicsinstitute.org

MEMBERS
(CONTINUED)

CENTRE FOR EYE RESEARCH AUSTRALIA

The Centre for Eye Research Australia (CERA) is Australia's leading eye research institute, dedicated to eliminating the major eye diseases that cause vision loss and blindness and to reducing their impact on the community.

CERA's comprehensive research program incorporates clinical, genetic and laboratory research into eye disease. Its population health research focuses on improving support and rehabilitation for people with vision loss.

In addition to treating eye disease and preventing vision loss, CERA is leading the way in vision regeneration research through its work in cytoprotection pharmacology and stem cell research.

CERA's Managing Director, Professor Jonathan Crowston, leads a team of over 130 clinician-scientists, researchers, students and support staff.

The research program is conducted by ten units.

- Clinical Genetics
- Cytoprotection Pharmacology
- Drug Delivery
- Glaucoma Research
- Health Services and Ocular Epidemiology Research
- Macular Research
- Neuroregeneration
- Ocular Genetics
- Population Health
- Surgical Research

Through its affiliation with the University of Melbourne and links to the Royal Victorian College of Ophthalmologists (RANZCO), CERA is helping to train the next generation of eye specialists.

CERA is located at the Royal Victorian Eye and Ear Hospital. The setting provides the ideal environment to conduct its world renowned translational research.

In 2011, a benchmarking exercise showed that CERA, and its affiliated University of Melbourne Department of Ophthalmology, ranked fourth in productivity among eye research groups internationally, on the basis of volume, quality and impact of scientific publications output.

www.cera.org.au

FLOREY NEUROSCIENCE INSTITUTES

The Florey Neuroscience Institutes continued to operate as the umbrella body for the Brain Research Institute, the Howard Florey Institute and the National Stroke Research Institute during 2011-12.

Led by Director, Professor Geoffrey Donnan AO, some 550 members of staff are committed to addressing the causes of brain disease affecting up to one in five Australians.

At the end of the financial year, we were putting the finishing touches to an amalgamation of the Florey Neuroscience Institutes and the Mental Health Research Institute. The amalgamation will occur on 1 August 2012, with the new organisation to be titled the Florey Institute of Neuroscience and Mental Health.

Since moving in 2011 into the Melbourne Brain Centre premises with their superb facilities in Parkville, Heidelberg and at The Royal Melbourne Hospital, we have increased our capacity to attract a wide range of talented scientists both nationally and internationally, including researchers from Stanford University, Leeds University and the University of California, Los Angeles.

During 2011-12 we built on our links to Austin Health and the Royal Melbourne Hospital, conducting research that underpins the future of medicine. Our imaging facilities are offering unparalleled access to the brain and internationally our staff are recognised for maximising the benefits of the state-of-the-art magnetic resonance equipment.

We are placed third in the world in terms of average citations per publication.

Research Focus

Ground-breaking work continues at the Florey with research undertaken in a number of basic and clinical areas. Better treatments for a range of neurological and psychiatric conditions are sought in:

- Addiction
- Cardiovascular Disease
- Depression
- Epilepsy
- Huntington's Disease
- Mental Illness
- Motor Neurone Disease
- Multiple Sclerosis
- Pain
- Parkinson's Disease
- Schizophrenia
- Stroke
- Traumatic Brain and Spinal Cord Injury

Divisions

- **Neurodegeneration** - led by Professor Phil Beart
- **Behavioural Neuroscience** - led by Associate Professor Andrew Lawrence and Professor Amy Brodtmann
- **Multiple Sclerosis** - led by Professor Trevor Kilpatrick
- **Imaging** - led by Professor Alan Connelly
- **Stroke** - led by Professors David Howells and Julie Bernhardt
- **Epilepsy** - led by Professors Graeme Jackson and Steve Petrou
- **Systems Neurophysiology** - led by Professors Robin McAllen and Richard Macdonell
- **Brain Development and Regeneration** - led by Professor Seong-Seng Tan
- **Neuropeptides** - led by Associate Professor Ross Bathgate

We Offer

- Human and Animal MRI
- Positron Emission Tomography – Computed Tomography (PET-CT)
- Advanced Microscopy
- Core Animal Services
- Behavioural Services
- Histology Services
- Fluorescence-activated Cell Sorting/FACS Facility

Neuroscience Trials Australia and the commercialisation of our core services take advantage of our expertise in clinical trials and analysis in the field of neuroscience. The Florey reached out to those in the biotechnology and pharmaceutical sectors requiring statistical analysis, project management, proof of concept and preclinical assessment of new therapies, through to access to strategic alliances with therapeutic disease groups.

Neuroscience Trials Australia – Bringing Innovation To Clinical Trials

Neuroscience Trials Australia is an Australian based, not-for-profit contract research organisation specialising in neuroscience clinical research. It is a wholly-owned subsidiary of The Florey with strategic alliances with many therapeutic disease groups.

The business provides access to key opinion leaders, sites and clinical trial expertise through a range of tailored services. Areas of expertise include stroke and stroke-related conditions, multiple sclerosis, epilepsy, Parkinson's disease, spinal cord injuries, Huntington's disease, neurosurgery, pain, neuromuscular disease and migraine. Studies sponsored by pharmaceutical companies, the biotechnology industry, granting bodies or institutions and investigator-initiated studies are served by this innovative addition to our organisation.

Translational Activities

The Florey is an active partner in several translational ventures funded through venture capital investments. For example, NeuProtect Pty Ltd is developing a new therapeutic for acute myocardial infarction. The lead agent is in late stage preclinical development prior to a phase I trial. The company has recently entered into an investment option with MedImmune Ventures based in the USA. The Parkinson's device for monitoring medication partnered via Global Kinetics Corporation continues to exceed development plans and is now in late stage clinical trials.

www.florey.edu.au

MEMBERS
(CONTINUED)

MELBOURNE HEALTH

Melbourne Health is Victoria's second largest public health service. It employs over 8,000 staff across its services, manages over 1,400 beds and has an operating budget of $800 million.

Melbourne Health provides comprehensive acute, sub-acute and community-based health care programs to the culturally and linguistically diverse communities of northern and western metropolitan Melbourne. It also provides general and specialist services to regional and rural Victorians and statewide services. In addition to providing clinical care, Melbourne Health has a key role in research and education to ensure world-class healthcare can continue to be delivered into the future.

Melbourne Health comprises:

- The Royal Melbourne Hospital - City Campus
- The Royal Melbourne Hospital - Royal Park Campus
- NorthWestern Mental Health
- Victorian Infectious Diseases Reference Laboratory

The Royal Melbourne Hospital is also home to The Melbourne Brain Centre, a state-of-the-art neurosciences facility offering new hope for Australians suffering from acute brain episodes such as stroke and degenerative brain disorders.

Melbourne Health, led by Chief Executive, Dr Gareth Goodier, delivers services to a population of over one million people living in Melbourne's northern and western region and a range of specialist services to all Victorians. The Royal Melbourne Hospital is one of only two adult trauma hospitals in Victoria.

Melbourne Health's Strategic Plan 2010-2015 confirms an ongoing and sustained commitment to our communities through a new Vision and Mission and confirmation of Our Values, while recognising the important contribution of staff, partners and patients in the development of, and continued commitment to our 'Passion for Caring - Achieving the Extraordinary'.

Our Vision

Passion for Caring - Achieving the Extraordinary

Our Mission

To provide world-class health care for our community. We will embrace discovery and learning, build collaborative relationships and engage our patients in their care.

Our Values

- Respect for the dignity, beliefs and abilities of every individual
- Caring and compassion
- Unity as a team and in embracing our communities
- Integrity by being open, honest and fair
- Discovery through passion for innovation

The five strategic goals in the 2010-2015 Strategic Plan reflect the organisation's response to the changing health care environment and our key challenges.

Our Strategic Goals

- Develop our workforce
- Improve the quality and safety of our services
- Develop and encourage strategic relationships
- Foster a culture of research and innovation
- Build a sustainable organisation

The Melbourne Health Strategic Plan 2010-15 is part of a broader strategic planning and performance framework, designed to enable the organisation to translate long-term strategic goals into day-to-day operations. The annual Melbourne Health Business Plan is the key link in realising the Melbourne Health Strategic Plan 2010-2015, with annual Business Plan actions directly linked to the strategic goals, objectives and actions articulated in the Strategic Plan.

www.mh.org.au

MENTAL HEALTH RESEARCH INSTITUTE

The Mental Health Research Institute (MHRI) engages in research which improves the lives of people affected by psychiatric/mental illness and dementia. The Institute, led by the Director, Professor Colin Masters, focuses its work in two major research programs; Neurodegeneration and Neuropsychiatry. Links to clinical services ensure research remains relevant and allows translation of research findings into clinical practice.

Neurodegeneration

- Alzheimer's disease - mechanism of neurotoxicity of A-beta amyloid protein, Amyloid Precursor Protein (APP), APP processing and reagent development
- Involvement in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, the largest longitudinal cohort study of its kind in the world, aiming to discern preclinical biomarkers, environmental contributions and treatment strategies for Alzheimer's disease
- Endogenous and exogenous factors that predispose to dementia, especially of the Alzheimer type
- Drug development and clinical trials, screening for dementia and pre-clinical diagnosis
- Role of oxidative stress in neurodegenerative diseases: Alzheimer's disease, Huntington's disease, motor neurone disease, Creutzfeldt-Jakob disease and the fronto-temporal dementias and tauopathies
- The normal and abnormal function of proteins which aggregate in these diseases and form pathogenic amyloid plaques

Neuropsychiatry

(Schizophrenia, Bipolar Disorder, Depression and related disorders)

- Identification of key genes and proteins through genomics/proteomics
- Regulation of major molecular therapeutic targets and neurobiological actions of dopamine, serotonin, acetylcholine and GABA
- Behavioural/phenotypic analysis of effect of pharmacological tools and modulating action of sex steroid hormones and stress
- Mechanism of action of atypical antipsychotics
- Cognitive deficits in schizophrenia and mood disorders
- Generation of delusions and auditory hallucinations (hearing voices)
- Role of oxidative free radicals in schizophrenia – fundamental and clinical studies
- Impact and mechanism of psychosocial treatment and collaborative therapy for people with a psychiatric illness

Neuroscience Platforms

MHRI is closely involved in the following neuroscience platforms.

- Australian Brain Bank Network
- Neurogenomics and Neuroproteomics

The Future

As of 1 August 2012 MHRI will amalgamate with The Florey Neuroscience Institutes to create the Florey Institute of Neuroscience and Mental Health. This amalgamation, combined with the 2011 co-location of some of MHRI's research groups at the Melbourne Brain Centre in Parkville and Heidelberg, will give our researchers access to greater know-how, technologies and equipment. Researchers from each of the participating organisations will take advantage of multidisciplinary teams to apply insights to related fields and to translate discoveries into new treatments.

www.mhri.edu.au

MEMBERS
(CONTINUED)

MONASH UNIVERSITY

The Monash University Brain Institute (MUBI), its associated research networks and the Faculty of Medicine, Nursing and Health Sciences bring together teams of scientists and clinicians from across the University and its affiliated centres and institutes to tackle major research challenges in the field of mental health and neuroscience.

The MUBI is led by the Director, Professor Jeffrey Rosenfeld, Professor of Surgery and Director, Department of Neurosurgery Alfred Hospital. Deputy Directors and heads of the main themes of MUBI are:

- Professor Kim Cornish, Head of the School of Psychology and Psychiatry (neurodevelopment and risk taking behaviour - with Professor Julie Stout)
- Associate Professor John Forsythe, Department of Materials Engineering (brain injury and repair)

Incorporating the University's campuses and many clinical sites and large teaching hospitals, Monash neuroscientists conduct leading edge research and clinical investigation in key areas of neuroscience and mental health. These include: neuroimaging, neuroinflammation, developmental neuroscience, developmental brain injury, regenerative medicine, ageing and neurodegeneration, brain plasticity and repair, Huntington's disease, cognition, control of movement and emotions, anxiety disorders, Alzheimer's disease, stroke, sensory physiology, schizophrenia, depression, autism, traumatic brain injury, bipolar affective disorder and intellectual disability.

The MUBI facilitates multi-disciplinary, cross-faculty research collaborations, building research capacity in the neurosciences and mental health and promoting the value of neuroscience research to the community, government and industry. Combining both laboratory based science and clinical research across many fields, we translate our findings into evidence based practice, policy and training.

The high quality and wide ranging research platforms at the Clayton Campus underpin much of this research. Collaborating Research Groups are the:

- Monash University Brain Imaging Centre - Professor Gary Egan
- Ritchie Centre of the Monash Institute for Medical Research - Professor Graham Jenkin
- Department of Pharmacology - Professor Chris Sobey
- Department of Physiology and the Australian Regenerative Medicine Institute - Dr James Bourne
- Australian Centre for Blood Disease - Professor Rob Medcalf (who has discovered the complex interactions of tissue-type plasminogen activator following traumatic brain injury)

The Monash Vision Group is developing a bionic vision device and is affiliated with MUBI.

'Direct to Brain' Bionic Eye – Monash Vision Group

The Monash Vision Group (MVG) comprises a team of more than 35 Monash University scientists working closely with a neurosurgical team at The Alfred Hospital. The MVG is making significant advances towards developing the visual equivalent of the bionic ear for people who are vision impaired or blind. MVG is working closely in this endeavour with Victorian-based industry partners: Grey Innovation, an engineering development and commercialisation company; and MiniFAB, a micro and nano-fabrication company with a detailed understanding of the regulatory pathways for medical device development.

Collaboration is strong, with Monash being Australia's largest university with expertise in signal processing, neuroscience, haptics and wireless communications and The Alfred Hospital's extensive experience in the successful implantation of electrodes directly into the brains of patients, for example, those with some forms of epilepsy.

The project, which commenced activities in 2010, targets the development of a cortical implant that bypasses the functions of the optical nerve and eye for stimulating the vision centre of the brain directly. The team aims to implant a device in a patient by early 2014. MVG's mission is to develop and commercialise a medical device that can serve to restore useful vision to people who are clinically blind, reflecting eye disease or physical injury. Although great progress has been made to date, further funding is required if the visual prosthesis being developed by MVG is to benefit vision-impaired patients and become a commercial reality.

Monash at a Glance

- Monash is Australia's most internationalised university
- It has more than 62,000 students from over 100 countries
- Monash University is a member of the prestigious Group of Eight (Go8) universities, recognised for excellence in teaching, learning, research and graduate outcomes
- Monash/Clayton cluster is home to CSIRO, the Australian Synchrotron, Monash Medical Centre, the Australian Stem Cell Centre and the Australian Regenerative Medicine Institute (ARMI)

The research in the University is underpinned by core technology platforms including:

- Structural Biology/ High-throughput Protein Production
- Genomics, Bioinformatics, Proteomics
- Optical Imaging
- Monoclonal Antibody Production (MATF)
- Mouse Phenomics/Transgenics
- BioMedical Imaging and Image Processing
- Drug Design and Development
- Biostatistics, Data-management, Bio-banking
- Engineering
- Material Sciences
- NanoFabriction

The University has a strong international reputation in medical research, including:

- Regenerative Medicine, Stem Cells and Developmental Biology
- Cardiovascular and Thrombosis
- Cancer
- Structural Biology and Drug Development
- Public Health and Epidemiology
- Infection and Immunity
- Inflammation, Allergy and Autoimmunity
- Health Science and Global Health
- Rural Health
- Indigenous Health
- Mental Health and Cognitive Neurosciences

Monash University has eight campuses: six in Australia, one in Malaysia and South Africa as well as a centre in Prato, Italy. The University has formed strong strategic partnerships in the UK (Warwick and Newcastle Universities), China (South East University, Suzhou) and India (Indian Institute of Technology Bombay, Mumbai).

Medicine, Nursing and Health Sciences

The Faculty of Medicine, Nursing and Health Sciences offers outstanding training through courses that include Medicine, Psychiatry, Behavioural Neuroscience, Biomedical Science, Psychology, Radiography and Medical Imaging. The Faculty has strong links with research institutes such as the Baker/IDI Research Institute, the Prince Henry's Institute for Medical Research, the Macfarlane Burnet Institute for Medical Research and Public Health, as well as with our major teaching hospitals, principally Monash Medical Centre, The Alfred Hospital and Box Hill Hospital. In total, the Faculty operates in 125 practices and 68 hospitals, providing outstanding facilities and resources for clinical teaching.

www.med.monash.edu.au

SWINBURNE UNIVERSITY OF TECHNOLOGY

Swinburne University of Technology is committed to quality research, with real-world applications. We deliver innovative research solutions to industry problems and our world-class research reputation is growing fast. We draw on our internationally recognised expertise and our outstanding infrastructure when collaborating with industry to produce quality solutions.

Swinburne has a selective and focused approach to the highest quality research, we have a vibrant academic community and we invest strategically in advanced facilities. This approach has been proven to have merit; Swinburne is now listed as one of the top 400 research universities in the world, according to the prestigious Shanghai Jiaotong (SHJT) university rankings.

Brain and Psychological Sciences Research Centre

The principal aim of the Brain and Psychological Sciences Research Centre (BPsyC) is to conduct high quality research in psychological sciences and human neuroscience in order to improve understanding of the human condition across the lifespan and contribute to the wellbeing of individuals and communities. BPsyC encompasses basic research from cellular and genetic science all the way through to brain and behavioural sciences. By increasing our understanding of human brain and psychological processes we aim to inform the development and evaluation of applications that improve the wellbeing of individuals with specific conditions and in specific contexts. We have particular interests in the study of compromised mental and cognitive health.

BPsyC brings together different disciplines with common interests in biopsychosocial factors associated with the healthy and dysfunctional human mind and brain. These include psychologists, psychophysiologists, neuroscientists and medical researchers.

Specific areas of interest include:

- Brain Functions, Structures, Connectivity and Dynamics
- Cellular Neuroscience
- Cognitive Neurosciences and Cognitive Neuropsychology
- Social and Affective Neurosciences
- Clinical Disorders and their Treatment
- Clinical and Forensic Psychology
- Normal and Abnormal Ageing and Infant Development
- The Neuroscientific Study of Decision-making

Our state-of-the-art equipment includes magnetic resonance imaging (MRI), magnetoencephalography (MEG), electroencephalography (EEG), trans-cranial magnetic stimulation (TMS), a radiofrequency (RF) laboratory, a computer-assisted interview facility (CATI), and a national internet-based psychological assessment and treatment centre (National e-Therapy Centre; NeTC). In addition, a clinical trials facility focuses on evaluating the effects of interventions on cognition, mental health, well-being and specific functions. Our research staff are actively involved in teaching and we have links to clinical services, industry and the community. Our partnerships and collaborations promote innovative solutions to scientific and community concerns. BPsyC strives to foster local and international research collaboration with government, industry and other academic institutions and has been successful in attracting nationally competitive grants, national and international industry contracts and government tenders.

Professor Michael Kyrios, Director of BPsyC, is a clinical psychologist who has a long history of commitment to teaching, research and clinical practice. In addition to working in the university sector, Mike has worked in general hospital, psychiatric, rehabilitation, primary care and private practice as well as with government. He has a particular interest in the development and dissemination of clinical applications based on evidence emerging from basic research using a range of methodologies. This focus on translational research and the integration of methodologies and findings across the lifespan is widespread across BPsyC. Professor Kyrios is supported by the BPsyC Deputy Directors, Professor Susan Rossell (Operations) and Professor Greg Murray (Administrative), both of whom have clinical backgrounds and international reputations in their respective fields.

BPsyC research staff: Prof Michael Kyrios - Prof Susan Rossell - Prof Greg Murray - Prof Glen Bates - Dr Sunil Bhar - Dr Joseph Ciorciari - Dr Christine Critchley - Dr Jordy Kaufman - A/Prof Ann Knowles - Prof David Liley - A/Prof Denny Meyer - Prof Sue Moore - Dr Richard Moulding - Dr Maja Nedeljkovic - Dr Richard Nibbs - Dr Conrad Perry - Dr Jeffrey Pfeifer - Dr Diane Sivasubramaniam - Dr Anna Thomas - Dr Ben Williams - Prof Andrew Wood - Dr Will Woods.

www.swinburne.edu.au/lss/bpsyc

THE UNIVERSITY OF MELBOURNE

The University of Melbourne continues to have an outstanding international profile in many facets of the neurosciences. Our cohort of eminent neuroscientists span the breadth of the University within the Faculty of Medicine, Dentistry and Health Sciences (FMDHS), the Melbourne School of Engineering and the Faculty of Science and where appropriate, extends to collaborative interaction with those focusing on social sciences. Research groups utilise multidisciplinary approaches to investigate a wide array of areas ranging from the neurobiology of cognitive function through to applied research designed to minimise the impact of major health care issues relevant to the spectrum of neurologic and psychiatric illness.

In recognition of its strength in the neurosciences, the University has enhanced its profile and capacity by inaugurating the Melbourne Neuroscience Institute (MNI). The MNI aims to promote excellence in the neurosciences, is the flagship for branding of University of Melbourne Neuroscience and is a principal vehicle for undertaking 'grand challenges' in the neurosciences and related disciplines. The MNI draws on the astounding breadth of neuroscience research activity at The University of Melbourne, whilst retaining and respecting the individual discipline strengths. This has been demonstrated by continued advances in the field of neuroscience led by our neuroscientists. The MNI aims to effect ground-breaking research via interdisciplinary partnerships, collaborations and strategic initiatives with the view of translation of these outputs to improved health and teaching outcomes. Our annual funding allocation from the University supports a core administrative team and research and RHD initiatives, including academic research salary support (including junior fellowships, recruitment of senior personnel), seed grants for the development of new interdisciplinary research projects, as well as key thematic areas.

Major Neuroscience Initiatives at the University of Melbourne Sponsored by MNI Include

- The Centre for Neural Engineering was officially launched in 2011 and draws together leading neuroscientists, neurologists, psychiatrists, cell biologists, geneticists, electrophysiologists, chemists, physicists and engineers to work on cutting edge bionics, computational neurobiology, sensors and imaging and stem cell and disease model research.
- Stem Cells Australia brings together Australia's premier life scientists to tackle the big questions in stem cell science in this Australian Research Council funded initiative. By linking Australia's leading experts in bioengineering, nanotechnology, stem cell biology, advanced molecular analysis and clinical research, the Stem Cells Australia collaboration is uncovering the fundamental mechanisms involved in stem cell regulation and differentiation and will translate that knowledge into innovative biotechnological and therapeutic applications. The unique multidisciplinary approach will also foster and train the next generation of Australian stem cell scientists, cementing Australia's future position in the field.
- The world-first Music, Mind & Wellbeing initiative (MMW) links neuroscience with music and social wellbeing through a unique set of collaborations spanning music, science, health, education and industry. MMW's bold research agenda involves a globally unique set of collaborations between researchers in music and science. MMW researchers have been actively developing new scientific approaches to music that incorporate perspectives from multiple disciplines. These perspectives are complementary and their integration is generating a new theoretical framework for music that is both translational and transformative.
- The Melbourne Brain Imaging Unit, led by Professor Roger Ordidge, Chair of Imaging Science, has been established through major funding from the Victorian Biomedical Imaging Capability and via the Federal Government Education Investment Fund, together with funds provided by the University of Melbourne, the Florey Neuroscience Institutes and the Mental Health Research Institute. The facility is envisioned to provide openly accessible world-class facilities for basic imaging research, allowing Australia to remain at the forefront in imaging-related science. The PET/CT has been installed and the first human participant has been scanned on the machine. A 7T MRI is to be located in the facility in 2013.

The MNI is also the University's vehicle for input into the Melbourne Brain Centre, a collaborative facility that incorporates three sites and is one of the largest neuroscience facilities in the world. The Melbourne Brain Centre at Parkville houses neuroscientists from the Florey Neuroscience Institutes, the Mental Health Research Institute and the University of Melbourne. The opportunity to bring together so many outstanding academics has strengthened connections between researchers and clinicians, enhancing their ability to work on common problems that are of importance to the community. This will help to attract and retain the best and brightest scientific minds from around the world. The Melbourne Brain Centre has developed into a vibrant research community across its facilities and in the broader scientific and research communities in the Parkville precinct and at Austin Health. The new facilities have capacity to accommodate over 700 staff and include laboratories, research offices, state-of-the-art technologies including magnetic resonance imaging suites and a brain bank, as well as translational research facilities on the hospital campuses.

THE UNIVERSTY OF MELBOURNE
(CONTINUED)

The University also has important neuroscience focused initiatives beyond the physical locality of the Melbourne Brain Centre's three sites. For example; The Centre for Neuroscience and the Department of Anatomy and Cell Biology have merged under the umbrella of the Department of Anatomy and Neuroscience. This provides a concrete focus for neuroscience-related research within the Faculty of Medicine, Dentistry and Health Sciences.

Research interests of the Department include neural development, myelin and glial biology, autonomic neuroscience and neural stem cell biology.

Within FMDHS, research strengths have also been grouped in a virtual way into eight research domains, one of which is the Neurosciences and Behavioural Sciences Domain, led by Associate Professor Ann Turnley of the Centre for Neuroscience Research and Department of Anatomy and Neuroscience, FMDHS. The research interests of these researchers are grouped into sub-domains and include:

Neurological Disorders
Such as Epilepsy, Stroke, Multiple Sclerosis, Neurotrauma and Neurodegenerative Diseases such as Alzheimer's Disease, Parkinson's Disease and Creuzfeldt-Jakob Disease, as well as Neural Regeneration

Behavioural Neurosciences/Psychology and Mental Health
Such as Human Cognition and Behavioural Neuroscience, Social Psychology and Human Development, Clinical Psychology and Clinical Neuropsychology and Psychiatry

Basic Neurosciences
Such as Developmental Neurobiology, Neurophysiology and Neuropharmacology, Autonomic and Sensory Systems, Molecular and Cellular Neuroscience

Advanced Technologies
Such as Stem Cell Sciences, Neural Engineering and Neural Imaging

The University, in partnership with The Florey continues to optimise the quality of the research experience and productivity of research higher degree students who are focusing on the neurosciences, whether their projects are undertaken within University laboratories or within independent medical research institutes. Research higher degree course work has been introduced through the institution of a series of discrete teaching and learning modules. Through this program we are enhancing the breadth of the knowledge base of our students in the neurosciences.

www.neuroscience.unimelb.edu.au

THE NSV TEAM

Andrew Milner PhD
CHIEF EXECUTIVE OFFICER AND MANAGING DIRECTOR

Andrew has been the CEO and Managing Director of Neurosciences Victoria since 2006.

Andrew obtained a BSc (Hons) at the University of Melbourne in 1976, a MSc degree at the University of Melbourne in 1980 and a PhD at the John Curtin School of Medical Research at the Australian National University in 1983.

Andrew is a Member of the Spinal Research Institute, a Member of the Advisory Board of the Melbourne Neuroscience Institute at the University of Melbourne and was appointed CEO of Neurosciences Australia in 2006.

Andrew is a Fellow of the Australian Society for Microbiology and has worked in animal health and agriculture as Head of Molecular Biology at the Victorian Institute of Animal Science and subsequently as Operations Manager at Daratech Pty Ltd. In the medical arena, he has worked as Pricing Manager for Zeneca and AstraZeneca in Australia, as Director of Development and Commercialisation for Kendle (Australia) and as Managing Director of Mimotopes Pty Ltd.

Clare Faux PhD
OFFICE MANAGER & RESEARCHER

Clare obtained a BSc (Hons) at Deakin University in 1995 and a PhD in neuronal stem cell development from The University of Melbourne in 2000. She subsequently undertook two post-doctoral positions in London; at The Institute of Child Health and at University College London, studying various aspects of nervous system development. She returned to Australia in 2009 to work in the Centre for Neuroscience at The University of Melbourne. Clare re-joined NSV in 2012, having previously worked for the Company as a Project Manager in 2001-02. Clare's extensive knowledge and experience in neuroscience provides valuable background to many varied facets of NSV's endeavours.

Irwin Saunders
CHIEF FINANCIAL OFFICER

Irwin Saunders is an FCPA of over 30 years' standing and joined NSV in 2008 as Chief Financial Officer. Prior to joining NSV, Irwin was Finance Manager of Australian Envelopes, Australia's largest envelope manufacturer. From 1998 to 2005 he was Financial Controller and Company Secretary of Mimotopes Pty Ltd, an Australian biotechnology company. He also has extensive experience in senior finance roles in the security printing and packaging, as well as scientific instrumentation industries.

Jackie Thompson
ACCOUNTS

Jackie commenced her employment with NSV in July 2004. She has over 20 years' experience working for a variety of companies, from a small computer software business to a large manufacturing/wholesale publicly owned company and has previously worked in accounts and administration within the hospitality industry.

Marion Thompson
COMPANY SECRETARY

Marion has an extensive background in providing executive support at the senior level. Prior to joining NSV in 2002, Marion spent some 20 years in the Victorian public sector in positions at the former Land Conservation Council and Museum Victoria.

Trisha Wooding
OFFICE MANAGER

Trisha has significant experience in administration and office management in both the public and private sectors and has provided support to high level executives in a number of companies. Trisha has been with NSV since its inception.

FINANCIALS

NEUROSCIENCES VICTORIA LIMITED, ABN 56 094 548 973

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 30 JUNE 2012

	2012 $	2011 $
Revenues	617,919	1,550,844
Employee benefits expense	-557,359	-605,259
Depreciation, amortisation and impairment losses	-7,160	-10,764
Business development expense	-55,250	-32,652
Insurance expense	-12,300	-13,565
Professional fees	-54,136	-56,537
Travel expense	-24,114	-40,448
Occupancy expense	-3,419	-6,066
AIBL study expense	0	-170,000
Other expenses	-37,850	-41,088
Scholarships	-50,000	0
Profit before tax	-183,669	574,465
Income tax expense	-	-
Profit for the year	-183,669	574,465
Other comprehensive income / (expense)	-	-
Total comprehensive income / (expense) for the year	-183,669	574,465

STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2012

	2012 $	2011 $
Current assets		
Cash and cash equivalents	622,222	416,138
Trade and other receivables	101,683	100,474
Other financial assets	2,360,900	2,360,900
Other assets	45,065	124,741
Total current assets	3,129,870	3,002,253
Non-current assets		
Property, plant and equipment	19,795	25,030
Financial assets	7	7
Total non-current assets	19,802	25,037
Total assets	3,149,672	3,027,290
Current liabilities		
Trade and other payables	180,665	199,640
Employee benefit liabilities	76,050	51,346
Other liabilities	287,931	0
Total current liabilities	544,646	250,986
Non-current liabilities		
Employee benefit liabilities	33,007	20,616
Total non-current liabilities	33,007	20,616
Total liabilities	577,653	271,602
Net assets	2,572,019	2,755,688
Equity		
Reserves	2,273,420	1,823,420
Retained earnings	298,599	932,268
Total equity	2,572,019	2,755,688

NEUROSCIENCES VICTORIA LTD
ACN 094 548 973

Level 2, 161 Barry Street
Carlton South VIC 3053
Australia

+61 3 8344 1802
+61 3 9348 1764
info@neurosciencesvic.com.au
www.neurosciencesvic.com.au